Novartis signs mRNA deal for about $7.8 billion with China's Abogen

Novartis and Abogen have signed an RNA licensing agreement, with Novartis paying $575 million upfront and up to $7.2 billion in milestones. The deal focuses on RNA therapeutics, potentially impacting both companies' financials and research pipelines.

Abogen Biosciences signed a licensing deal with Novartis for its experimental mRNA-based autoimmune disease therapy, ABO2203, securing a $575 million upfront payment and up to $7.2 billion in potential milestone payments. Novartis gains exclusive worldwide rights to the drug candidate, which targets B cells involved in autoimmune diseases. The deal is subject to customary closing conditions, including regulatory approvals.

Novartis and Abogen have signed a deal for RNA therapeutics, with $575 million upfront and up to $7.2 billion in milestones. The agreement focuses on mRNA technology, with Novartis gaining rights to develop and commercialize certain products. According to the companies, the collaboration aims to advance RNA-based treatments.

Novartis (NVS) announced a $575M upfront licensing deal with Abogen Biosciences, with up to $7.2B in milestone payments. The deal grants NVS rights to ABO2203, an mRNA-encoded T-cell engager for autoimmune diseases. NVS offers a 3.39% dividend yield, a 43% payout ratio, and a GF Score of 81/100, indicating strong fundamentals. The stock is trading 8.2% above its GF Value of $130.38. Institutional interest is mixed, with 17 gurus holding shares but recent trimming observed.

Abogen, a Chinese biotech company, announced a $7.8 billion licensing and option agreement with Swiss drug maker Novartis to develop RNA-based therapies, according to Abogen.

Chinese biotech firm Abogen has signed a $7.8 billion licensing and option agreement with Swiss drugmaker Novartis to develop RNA-based therapies, according to Abogen.